Bayrak Arzu, Cetin Bugra, Meteris Handan, Kesebir Sermin
Department of Psychiatry, Erenkoy Training and Research Hospital for Psychiatric and Neurological Diseases, Istanbul, Turkey.
North Clin Istanb. 2015 Dec 25;2(3):243-246. doi: 10.14744/nci.2015.63634. eCollection 2015.
In literature, there are more than hundred cases of extrapyramidal symptoms (EPS) associated with selective serotonin reuptake intibitors (SSRI) whereas EPS case reports associated with serotonin noradrenaline reuptake inhibitors (SNRI) are in a relatively small number. A SNRI group drug duloxetine that is used for indication of major depression since 2004 is a double acting antidepressant that acts by blocking serotonin and noradrenaline reuptake. Side effects of duloxetine on extrapyramidal system are not expected due to low affinity to D2 receptors. In this case, report manifestations of parkinsonism developed in a patient who used duloxetine for major depression are presented. Since any duloxetine induced EPS case has not reported so far, we have thought that this case can contribute to the literature.
在文献中，有超过一百例与选择性5-羟色胺再摄取抑制剂（SSRI）相关的锥体外系症状（EPS）病例，而与5-羟色胺去甲肾上腺素再摄取抑制剂（SNRI）相关的EPS病例报告数量相对较少。自2004年起用于治疗重度抑郁症的一种SNRI类药物度洛西汀是一种双效抗抑郁药，通过阻断5-羟色胺和去甲肾上腺素再摄取起作用。由于对D2受体亲和力低，预计度洛西汀对锥体外系无副作用。本文报告了一名使用度洛西汀治疗重度抑郁症的患者出现帕金森症的表现。鉴于目前尚未有任何度洛西汀诱发EPS的病例报告，我们认为该病例可为相关文献提供补充。
